| Macrocyclization strategies for cyclic peptides and peptidomimetics C Bechtler, C Lamers RSC Medicinal Chemistry 12 (8), 1325-1351, 2021 | 136 | 2021 |
| Revealing the macromolecular targets of complex natural products D Reker, AM Perna, T Rodrigues, P Schneider, M Reutlinger, B Mönch, ... Nature chemistry 6 (12), 1072-1078, 2014 | 134 | 2014 |
| Molecular tuning of farnesoid X receptor partial agonism D Merk, S Sreeramulu, D Kudlinzki, K Saxena, V Linhard, SL Gande, ... Nature communications 10 (1), 2915, 2019 | 81 | 2019 |
| Nonacidic farnesoid X receptor modulators D Flesch, SY Cheung, J Schmidt, M Gabler, P Heitel, J Kramer, A Kaiser, ... Journal of Medicinal Chemistry 60 (16), 7199-7205, 2017 | 81 | 2017 |
| Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review (2008–present) C Lamers, M Schubert-Zsilavecz, D Merk Expert opinion on therapeutic patents 22 (7), 803-841, 2012 | 79 | 2012 |
| Cyclic peptide FXII inhibitor provides safe anticoagulation in a thrombosis model and in artificial lungs J Wilbs, XD Kong, SJ Middendorp, R Prince, A Cooke, CT Demarest, ... Nature communications 11 (1), 3890, 2020 | 76 | 2020 |
| The promiscuous profile of complement receptor 3 in ligand binding, immune modulation, and pathophysiology C Lamers, CJ Plüss, D Ricklin Frontiers in immunology 12, 662164, 2021 | 65 | 2021 |
| Extending the structure–activity relationship of anthranilic acid derivatives as Farnesoid X receptor modulators: Development of a highly potent partial Farnesoid X receptor … D Merk, C Lamers, K Ahmad, R Carrasco Gomez, G Schneider, ... Journal of Medicinal Chemistry 57 (19), 8035-8055, 2014 | 63 | 2014 |
| N-Benzylbenzamides: A Novel Merged Scaffold for Orally Available Dual Soluble Epoxide Hydrolase/Peroxisome Proliferator-Activated Receptor γ Modulators R Blöcher, C Lamers, SK Wittmann, D Merk, M Hartmann, L Weizel, ... Journal of medicinal chemistry 59 (1), 61-81, 2016 | 55 | 2016 |
| Overcoming the shortcomings of peptide-based therapeutics C Lamers Future Drug Discovery 4 (2), FDD75, 2022 | 53 | 2022 |
| Compstatins: the dawn of clinical C3-targeted complement inhibition C Lamers, DC Mastellos, D Ricklin, JD Lambris Trends in pharmacological sciences 43 (8), 629-640, 2022 | 48 | 2022 |
| Anthranilic acid derivatives as novel ligands for farnesoid X receptor (FXR) D Merk, M Gabler, RC Gomez, D Flesch, T Hanke, A Kaiser, C Lamers, ... Bioorganic & medicinal chemistry 22 (8), 2447-2460, 2014 | 40 | 2014 |
| Medicinal chemistry and pharmacological effects of Farnesoid X Receptor (FXR) antagonists C Lamers, M Schubert-Zsilavecz, D Merk Current topics in medicinal chemistry 14 (19), 2188-2205, 2014 | 37 | 2014 |
| Anthranilic acid derivatives as nuclear receptor modulators—Development of novel PPAR selective and dual PPAR/FXR ligands D Merk, C Lamers, J Weber, D Flesch, M Gabler, E Proschak, ... Bioorganic & medicinal chemistry 23 (3), 499-514, 2015 | 36 | 2015 |
| Design and synthesis of dual modulators of soluble epoxide hydrolase and peroxisome proliferator-activated receptors E Buscató, R Blöcher, C Lamers, FM Klingler, S Hahn, D Steinhilber, ... Journal of medicinal chemistry 55 (23), 10771-10775, 2012 | 29 | 2012 |
| Complement‐targeted therapeutics: an emerging field enabled by academic drug discovery C Lamers, D Ricklin, JD Lambris American Journal of Hematology 98, S82-S89, 2023 | 21 | 2023 |
| Insight into mode-of-action and structural determinants of the compstatin family of clinical complement inhibitors C Lamers, X Xue, M Smieško, H van Son, B Wagner, N Berger, G Sfyroera, ... Nature Communications 13 (1), 5519, 2022 | 20 | 2022 |
| Identification of pirinixic acid derivatives bearing a 2-aminothiazole moiety combines dual PPARα/γ activation and dual 5-LO/mPGES-1 inhibition T Hanke, C Lamers, RC Gomez, G Schneider, O Werz, ... Bioorganic & medicinal chemistry letters 24 (16), 3757-3763, 2014 | 17 | 2014 |
| Novel prostaglandin receptor modulators–Part II: EP receptor modulators; a patent review (2002–2012) D Flesch, D Merk, C Lamers, M Schubert-Zsilavecz Expert opinion on therapeutic patents 23 (2), 233-267, 2013 | 15 | 2013 |
| SAR studies on FXR modulators led to the discovery of the first combined FXR antagonistic/TGR5 agonistic compound C Lamers, D Merk, M Gabler, D Flesch, A Kaiser, M Schubert-Zsilavecz Future medicinal chemistry 8 (2), 133-148, 2016 | 14 | 2016 |
